

## **AMENDMENTS TO THE CLAIMS**

**1. (Currently amended)** A method for treating inflammatory disease of the external segment or the anterior segment of the eye, which comprises administering to the eye an aqueous eye drop ~~consisting essentially of~~ comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate ~~thereof~~ thereof, and at least one organic amine selected from the group consisting of ~~an amino acid, an alkanolamine, a piperazine and an aminoalkylsulfonic acid~~ arginine, histidine, aspartic acid, glutamic acid, serine, threonine, cysteine, phenylalanine, isoleucine, monoethanolamine, diethanolamine, triethanolamine, trometamol, (2-4-(2-hydroxyethyl)-1-piperazinyl)ethanesulfonic acid, 1,4-bis(2-sulfoethyl)-piperazine, ethylene diamine, trimethylene diamine, N,N'-bis(3-sulfopropyl)ethylene diamine, aminomethylsulfonic acid and aminoethylsulfonic acid once a day, and maintaining a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in the anterior aqueous humor of the eye.

**2. (Cancelled)**

**3. (Previously presented)** The method according to claim 1, wherein the concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof in the aqueous eye drop is 0.01 to 0.5w/v%.

**4. (Cancelled)**

**5. (Currently amended)** The method according to claim 1, wherein the organic amine is an amino acid selected from the group consisting of arginine, histidine, aspartic acid, glutamic acid, serine, threonine, cysteine, phenylalanine and isoleucine, and its concentration is 0.35 to 5w/v%.

**6. (Currently amended)** The method according to claim 1, wherein the organic amine is ~~an alkanolamine~~ selected from the group consisting of monoethanolamine, triethanolamine and trometamol, and its concentration is 0.15 to 0.95w/v%.

**7. (Currently amended)** The method according to claim 1, wherein the ~~alkanolamine~~ organic amine is trometamol.

**8. (Cancelled)**

**9. (Currently amended)** The method according to claim 1, wherein the organic amine is a piperazine-2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid or 1,4-bis(2-sulfoethyl)piperazine, and it is contained at a concentration of 0.05 to 5w/v% in the aqueous eye drop.

**10. (Currently amended)** The method according to claim 1, wherein the organic amine is ~~an aminoalkylsulfonic acid~~ aminomethylsulfonic acid or aminoethylsulfonic acid, and its concentration is 0.05 to 5w/v%.

**11. (Currently amended)** The method according to claim 10, wherein the ~~aminoalkylsulfonic acid~~ organic amine is aminoethylsulfonic acid.

**12-35. (Cancelled)**